Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,014,671,232
  • Shares Outstanding, K 945,384
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 19,815 M
  • EBITDA $ 21,582 M
  • 60-Month Beta 0.35
  • Price/Sales 15.66
  • Price/Cash Flow 75.67
  • Price/Book 42.70

Options Overview Details

View History
  • Implied Volatility 39.20% (-0.01%)
  • Historical Volatility 28.19%
  • IV Percentile 69%
  • IV Rank 35.60%
  • IV High 64.53% on 04/07/25
  • IV Low 25.20% on 02/06/25
  • Expected Move (DTE 8) 31.72 (3.07%)
  • Put/Call Vol Ratio 0.97
  • Today's Volume 69,643
  • Volume Avg (30-Day) 39,294
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 390,377
  • Open Int (30-Day) 392,076
  • Expected Range 1,001.25 to 1,064.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 7.49
  • Number of Estimates 7
  • High Estimate 8.72
  • Low Estimate 7.00
  • Prior Year 5.32
  • Growth Rate Est. (year over year) +40.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,012.57 +2.01%
on 01/15/26
1,133.95 -8.91%
on 01/08/26
-29.22 (-2.75%)
since 12/15/25
3-Month
783.85 +31.78%
on 10/17/25
1,133.95 -8.91%
on 01/08/26
+206.40 (+24.97%)
since 10/15/25
52-Week
623.78 +65.60%
on 08/08/25
1,133.95 -8.91%
on 01/08/26
+286.23 (+38.33%)
since 01/15/25

Most Recent Stories

More News
Stocks Boosted by Chip Demand Optimism

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.60%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. March E-mini...

MSTR : 170.91 (-4.70%)
BLK : 1,156.65 (+5.93%)
AMAT : 319.08 (+5.69%)
MPC : 177.59 (-1.93%)
SNDK : 409.24 (+5.53%)
ADI : 302.10 (+1.38%)
MLTX : 16.35 (-6.09%)
$IUXX : 25,547.08 (+0.32%)
COIN : 239.28 (-6.48%)
ASML : 1,331.60 (+5.37%)
ZNH26 : 112-065 (-0.01%)
OXY : 43.17 (-2.59%)
Why Eli Lilly (LLY) Stock Is Down Today

Why Eli Lilly (LLY) Stock Is Down Today

LLY : 1,032.97 (-3.76%)
Stocks Supported by Strength in Chip Makers and US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.49%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.07%. March E-mini S&P futures (ESH26...

BLK : 1,156.65 (+5.93%)
MSTR : 170.91 (-4.70%)
AMAT : 319.08 (+5.69%)
MPC : 177.59 (-1.93%)
SNDK : 409.24 (+5.53%)
ADI : 302.10 (+1.38%)
MLTX : 16.35 (-6.09%)
$IUXX : 25,547.08 (+0.32%)
ASML : 1,331.60 (+5.37%)
ZNH26 : 112-065 (-0.01%)
OXY : 43.17 (-2.59%)
ESH26 : 7,000.50 (+0.27%)
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...

ONCY : 0.9730 (-7.33%)
BCT.TO : 6.25 (-7.27%)
ACRV : 1.8700 (+2.19%)
LLY : 1,032.97 (-3.76%)
BCTX : 4.49 (-7.61%)
GLSI : 27.19 (-7.17%)
CATX : 2.48 (-5.34%)
A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

SFD : 23.41 (-0.17%)
CRWV : 95.01 (+5.80%)
AKTS : 20.56 (-1.20%)
LLY : 1,032.97 (-3.76%)
MDLN : 42.71 (-1.61%)
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.

VTYX : 13.86 (unch)
NVO : 57.12 (-3.04%)
LLY : 1,032.97 (-3.76%)
Nvidia Stock Could Be Just a Few Weeks Away from a Major Downside Catalyst. How to Play NVDA Here.

DeepSeek is set to launch its latest V4 model in just a few weeks, drawing parallels to its launch in January 2025 of its R1 model that triggered a selloff in NVDA and other AI names.

NVDA : 187.05 (+2.13%)
TMO : 624.65 (+0.45%)
LLY : 1,032.97 (-3.76%)
What to Expect From Eli Lilly’s Q4 2025 Earnings Report

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.

XLV : 156.96 (-0.57%)
$SPX : 6,944.47 (+0.26%)
LLY : 1,032.97 (-3.76%)
This NVIDIA Partnership Shows How Big AI Can Really Get

NVIDIA is well-positioned to dominate AI markets across industries and verticals for years to come; analysts point to a 40% upside.

NVDA : 187.05 (+2.13%)
ACHR : 8.86 (-0.56%)
CAT : 647.18 (+1.32%)
LLY : 1,032.97 (-3.76%)
This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

CVS : 81.36 (+2.56%)
VHT : 291.96 (-0.53%)
NVO : 57.12 (-3.04%)
JNJ : 219.57 (+0.47%)
MRK : 110.97 (-0.04%)
HCA : 483.80 (+1.04%)
ABBV : 216.75 (-2.32%)
UNH : 338.96 (+1.19%)
ELV : 381.93 (+2.44%)
PFE : 25.89 (+1.21%)
TSLA : 438.57 (-0.14%)
LLY : 1,032.97 (-3.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,117.97
2nd Resistance Point 1,092.81
1st Resistance Point 1,062.89
Last Price 1,032.97
1st Support Level 1,007.81
2nd Support Level 982.65
3rd Support Level 952.73

See More

52-Week High 1,133.95
Last Price 1,032.97
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar